St. Louis site strengthens integrated support for biopharma manufacturing

RADNOR, Pa., April 13, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced the expansion of its North American quality control capabilities with the addition of advanced microbial and stability testing at its St. Louis manufacturing site.

The investment builds on Avantor's established global quality infrastructure, expanding and localizing capabilities to better support U.S.-based biopharma manufacturing and further accelerate service for customers.

Key Highlights

  • Expands GMP-aligned microbial testing and ICH-compliant stability testing and storage in North America
  • Localizes testing previously conducted across third-party labs and Avantor's global network, bringing critical capabilities closer to U.S. manufacturing operations
  • Supports 2,000+ microbial samples annually within Avantor's internal network
  • Enables faster turnaround times, improved data visibility, and reduced supply chain complexity

Expanding and Consolidating U.S. Quality Infrastructure

The enhanced St. Louis facility now offers integrated microbial and stability testing aligned with global regulatory standards, supporting regulated biopharma applications and reinforcing Avantor's commitment to quality, compliance, and customer service.

By consolidating these capabilities into a single North American location, Avantor reduces reliance on external laboratories and minimizes cross-border sample movement, improving efficiency while maintaining consistent global quality standards.

Improving Speed, Control and Supply Chain Efficiency

Integrating testing into one location enables accelerated time to market, more interconnected lab compliance and in-house expertise, and more streamlined operations across the biopharma supply chain.